Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

July 01, 1998; 51 (1 Suppl 1) Articles

Abnormalities of neural circuitry in Alzheimer's disease

Hippocampus and cortical cholinergic innervation

Changiz Geula
First published July 1, 1998, DOI: https://doi.org/10.1212/WNL.51.1_Suppl_1.S18
Changiz Geula
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Abnormalities of neural circuitry in Alzheimer's disease
Hippocampus and cortical cholinergic innervation
Changiz Geula
Neurology Jul 1998, 51 (1 Suppl 1) S18-S29; DOI: 10.1212/WNL.51.1_Suppl_1.S18

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
272

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Severe pathology in Alzheimer's disease (AD) results in marked disruption of cortical circuitry. Formation of neurofibrillary tangles, neuronal loss, decrease in dendritic extent, and synaptic depletion combine to halt communication among various cortical areas, resulting in anatomic isolation and fragmentation of many cortical zones. The clinical manifestation of this disruption is severe and debilitating cognitive dysfunction, often accompanied by psychiatric and behavioral disturbances and a diminished ability to perform activities of daily living. However, different cortical circuits are not equally vulnerable to AD pathology. In particular, two cortical systems that appear to be involved in the neural processing of memory are selectively vulnerable to degeneration in AD. One consists of connections between the hippocampus and its neighboring cortical structures within the temporal lobe. The second is the cortical cholinergic system that originates in neurons within the basal forebrain and innervates the entire cortical mantle. The circuitry in these systems shows early and severe degenerative changes in the course of AD. The selective vulnerability of these circuits is the probable reason for the early and marked loss of memory observed in these patients. This review presents current knowledge of the general pattern of cortical circuitry, followed by a summary of abnormalities of this circuitry in AD. The cortical circuits the exhibit selective pathology in AD are described in greater detail. Therapeutic implications of the abnormal circuitry in AD are also discussed. For therapies to be effective, early diagnosis of AD is necessary. Future efforts at AD therapy must be combined with an equally intense effort to develop tools capable of early diagnosis of AD, preferably at a preclinical stage before the onset of cognitive symptoms.

At first encounter, the basic elements that enable the nervous system to execute its functions appear exceedingly simple. These include a transmitting component, which is usually an axon, a point of transmission, which is subserved by the synaptic specialization, and a receptive component, represented by the cell body and dendrites. These elements make up a simple neural "circuit." This simplicity, however, vanishes quickly when the multiple circuits that underlie channeling of information through the nervous system are considered collectively. Each neuron receives input from a large number of axons and, in turn, transmits signals to many other neurons. Neural transmission takes place electrically, through gap junctions, or chemically, through the deployment of a bewildering variety of neurotransmitters and modulating peptides. Neurotransmitters, in turn, produce their postsynaptic effects through interaction with a multiplicity of receptors. In some instances, transmission bypasses the synapse completely, occurring through passive diffusion of the transmitter. Finally, processing of information in the nervous system is accomplished through the utilization of a network of axons and synapses involving many waystations. Viewed in this light, the neural circuitry involved in the production of the simplest behavior becomes exceedingly complex.

Neurodegenerative disorders, including Alzheimer's disease (AD), produce their clinical symptoms by disrupting, to various degrees, the normal circuitry of the brain. The role of the scientist in relation to these disorders is to discover which specific circuits are vulnerable to the neurodegenerative insult and the reasons for such vulnerability. To be of clinical relevance, the vulnerable circuits must be related to the clinical symptoms. In AD, the major clinical symptoms occur in the cognitive and behavioral domains, implicating the cerebral cortex as a major site of pathology. The earliest and most prominent cognitive abnormality in this disorder is loss of memory. A large body of evidence indicates that the specific cortical circuits involved in memory processing are selectively vulnerable to pathology in AD. This review, presents current knowledge of the general circuitry of the primate cerebral cortex, followed by a summary of available evidence on specific circuits vulnerable to AD pathology.

Circuitry of the primate cerebral cortex. On the basis of cytoarchitectural characteristics and functional affiliations, the cerebral cortex of the primate brain can be divided into five cortical types or zones1,2 (see Mesulam2 for review). These include the core limbic, paralimbic, multimodal (heteromodal) association, unimodal association, and sensorimotor cortical areas. The core limbic structures are the most primitive type of cortex and have the least differentiated lamination, containing two or three layers of neurons. There are two core limbic cortical zones in the primate brain: the hippocampus and the piriform (primary olfactory) cortex. Paralimbic areas represent zones of cortical transition between the poorly differentiated core limbic and the six-layered isocortical zones. Accordingly, paralimbic cortical areas contain more and better-differentiated layers than the core limbic zones but do not contain the six layers characteristic of isocortex. The paralimbic zones in the primate brain include the parahippocampal gyrus (including the entorhinal cortex), the cingulate cortex, the temporal pole, the caudal orbitofrontal cortex, and the insula. The multimodal association areas, which include the prefrontal cortex, the inferior parietal lobule, and perhaps the banks of the superior temporal sulcus, have the definite appearance of six-layered isocortex and, as their designation implies, respond to and process information from two or more sensory modalities. Each of the unimodal association areas, on the other hand, processes information from a single sensory modality. Therefore, each primary sensory cortical area is flanked by an association area of the same name. Unimodal association areas can be distinguished from multimodal areas by their increased laminar differentiation, including clear sublamination of layers III and V and increased granularization of layers II and IV. Finally, the sensorimotor cortical zones represent perhaps the most differentiated types of cortex and allow sensory input into the cortex and motor output from the cortex.

Our knowledge of the cortical connectivity of the primate brain is derived, in great part, from studies in nonhuman primates. The parcellation of the primate cortex presented above is also useful in understanding the pattern of cortical connections. This pattern is shown infigure 1. In general, areas comprising one type of cortex have their primary connections with the cortical areas, that are one level above or below them in terms of cytoarchitectonic differentiation.2 For example, the primary vertical connections of paralimbic areas are with core limbic zones on the one hand and multimodal association areas on the other.3-5 Similarly, the multimodal association areas have their primary connections with the paralimbic and unimodal association areas.2 In addition, various cortical areas of the same type share extensive horizontal connections. For example, all paralimbic areas have extensive horizontal interconnections. The horizontal connections are well developed in the multimodal association, paralimbic, and limbic zones but constitute a minor component in the primary sensorimotor and unimodal association areas.2,4,5 It should be kept in mind that this schema applies to major connections among cortical areas. There are cortical connections that violate this general pattern, but these are minor connections.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. Schematic representation of various cortical types and their pattern of connectivity. Cortical types are listed in the order of increasing cytoarchitectonic development from bottom to top. The vertical lines indicate major connections among the various cortical types. Thus, the major vertical connections of each zone are with areas immediately above and below it in terms of cytoarchitectonic differentiation. Most of these connections are reciprocal. Diagonal lines represent cortical input from subcortical nuclei with diffuse projections, such as the cholinergic neurons of the basal forebrain. The input from these subcortical nuclei reaches virtually all zones of cortex.

This pattern of cortical connectivity allows integration of input from the external world with information concerning the internal condition of the organism so that appropriate responses can be executed. Information concerning the external world is received by the primary sensory areas via thalamic relay nuclei. After an initial processing, this sensory input is channeled to the appropriate unimodal association area for further elaboration. The core limbic regions, on the other hand, are in touch with the internal environment (e.g., needs, drives) through their extensive connections with the hypothalamus (which has been called the head ganglion of the internal milieu) and with subcortical components of the limbic system such as the amygdala, the septal region, and the substantia innominata.2,6 Information concerning the internal milieu is further processed in paralimbic zones. The first opportunity for the integration of information about the external world and the internal environment is afforded by the multimodal association areas. Because of this integrative capacity, the multimodal association areas of the human brain are major contributors to higher cognitive functions. Finally, the multimodal association zones communicate with the supplementary and primary motor cortices to allow an appropriate response. As figure 1 implies, the vertical access to information at various levels of cortical organization is bi-directional. Thus, core limbic structures have access to processed sensory information from multimodal association areas via paralimbic zones. Similarly, sensorimotor areas have access to processed information concerning the internal environment through multimodal association areas via unimodal association zones. In short, the pattern of cortical connectivity in the primate brain allows channeling of information along specific neural circuits or networks of circuits. The uninterrupted channeling of information through these circuits is the basis of normal cognitive function.

The primate cerebral cortex is the recipient of a second type of input.2,7 This input originates, in its entirety, outside of cortex in a number of subcortical regions (figure 1). These include dopaminergic neurons of the ventral tegmental area, noradrenergic neurons of the locus ceruleus, cholinergic neurons of the pontomesencephalic reticular formation, serotonergic neurons of brainstem raphe nuclei, lateral and medial hypothalamus, intralaminar thalamic nuclei, and cholinergic neurons of the basal forebrain. Unlike the subcortical input from thalamic sensory relay nuclei, which channel information to specific cortical areas, the projections from each of these subcortical regions is diffuse, reaching virtually the entire cortical mantle. Therefore, the activity of these nuclei is capable of influencing information processing in many cortical areas simultaneously. For this reason, it has been suggested that input from these subcortical nuclei may function to set the general"state" of cortical circuitry, in contrast to other cortical connections that channel information through particular circuits.2

Pathologic hallmarks of AD. In the first report on the disease that now bears his name, Alois Alzheimer8 described two types of lesions in the brain of his patient: "tangled bundle of fibrils" and"miliary foci resulting from the deposit of a unique substance." The terms commonly used today to designate these lesions are the neurofibrillary tangle and the senile plaque, respectively. The plaque is a complex structure found in the neuropil and consists of amyloid (Aβ), abnormal neurites, and glial cells.9 Several types of plaques have been described, and it is believed that these represent maturational stages of a single pathologic process. According to this hypothesis, amyloid is first deposited in the form of a diffuse plaque. Gradually, this amyloid is transformed into fibrils, which are believed to be toxic to neurons and disruptive to neuronal processes present in the neuropil.10 Still later, dystrophic neurites become associated with the plaque, presumably representing degeneration of neuronal components damaged by amyloid.

Tangles are intracellular accumulations of cytoskeletal elements in the cytoplasm and are made of paired helical filaments.9 A major component of tangles is abnormally phosphorylated τ (PH-τ, a microtubule-associated protein), and antibodies against this element can be used to stain tangles.11 PH-τ is also a component of plaque neurites and neuropil threads, which are believed to represent degenerating processes (dendrites and perhaps axons) of neurons with tangles.12 Therefore, all parts of a neuron are vulnerable to cytoskeletal pathology in AD. Tangles damage neurons by disrupting transport of various cellular components and by displacing cytoplasmic elements, thus leading to degeneration of the neurons in which they are formed.

A wealth of recent evidence indicates that Aβ, which accumulates in plaques, may be a major contributor to the pathology of AD.13,14 Aβ deposition in plaques, however, appears to represent an early pathologic event, because it also occurs in aged individuals with or without mild cognitive disturbance.15-17 Cytoskeletal abnormality (i.e., tangles, plaque neurites, neuropil threads) and neuronal loss, on the other hand, are probably later events in the cascade of AD pathology, which coincide with the clinical manifestation of dementia and are correlated with dementia severity.18,19 Therefore, the disruption of neural circuits in AD is most convincingly explained by the cytoskeletal pathology and neuronal loss observed in this disease.

General pattern of cortical pathology in AD. At advanced stages of the disease process, which is the point at which the majority of AD brains come to autopsy, most of the cerebral cortex and many subcortical areas contain large numbers of plaques and tangles.19-21 Plaque density is usually high and is relatively homogeneous among most cortical areas. Within the paralimbic and especially the core limbic and some sensorimotor areas, relatively lower densities of plaques are found compared with other cortical areas.19-21 Cortical tangle density, on the other hand, displays considerable regional variation. Core limbic and paralimbic areas contain the highest density of tangles in the AD cortex. The next highest density is found in multimodal association areas, followed by unimodal association zones. Sensorimotor areas contain only a low density of tangles.20,21 Neuropil threads and, to a lesser extent, the neuritic component of plaques are distributed in parallel with tangles in the above cortical regions. Although tangles can be found without neuronal loss, most cortical areas with a high density of tangles also display significant loss of neurons.22,23 In addition, tangle-bearing regions of cortex display substantial loss of synapses24,25 and decreases in neuronal dendritic extent.22,26 An inevitable consequence of this pathology is the disruption of neural circuits and isolation of affected areas from the rest of the cortex. Disruption of neural circuitry in such a large number of cortical areas helps explain the cognitive nature of abnormalities in AD.

Cortical circuitry in AD is further disrupted by the withdrawal of the influence of subcortical nuclei with diffuse cortical projections.7 Although tangle formation and neuronal loss are observed in a number of subcortical structures, the nuclei with diffuse cortical projections are more severely affected.27 Some of these nuclei, such as the cholinergic neurons of the basal forebrain and the raphe nuclei, contain a very high density of tangles.27-29

Cortical circuits selectively vulnerable to Alzheimer pathology. Loss of memory is the earliest clinical abnormality and the most salient cognitive deficit in AD. By implication, the neural systems that subserve learning and memory should display selective, early, and substantial vulnerability to AD-type pathology. Pathologic observations in AD brains have provided overwhelming support for this implication. Two networks of circuits that have been shown to be involved in various aspects of memory processing exhibit such selective vulnerability in AD. One consists of the pathways that connect the hippocampus and the entorhinal region with the rest of the cortex. These pathways belong to the type of circuit that subserves "channel" functions. The other is the cholinergic system of the basal forebrain, which is a subcortical region with diffuse cortical projections. Here the normal anatomy of these circuits is described, followed by a summary of evidence on their selective vulnerability in AD and a discussion of the functional implications of this vulnerability.

Hippocampus and entorhinal cortex. The hippocampus and entorhinal cortex are related structures located in the medial aspect of the temporal lobe.2,6 The hippocampus is a core limbic structure and is therefore cytoarchitectonically less differentiated than most other cortical areas. It consists of the dentate gyrus (DG), the Ammon's horn [cornu Ammonis (CA)], and the subiculum6(figure 2A). The DG is composed of three layers: the inner polymorphic layer, the granule cell layer, and the cell-free molecular layer (figure 2B). Four distinct sectors can be identified within the CA field. The CA4 sector is surrounded by the DG and is followed distally by the CA3, CA2, and, the largest sector, CA1(figures 2B and C). The CA1-CA4 sectors consist of one major cell-rich layer, which contains pyramidal neurons (hence referred to as the pyramidal cell layer), and two or three other layers, which are composed primarily of axons and dendrites. The thickness of the pyramidal cell layer and the density of neurons within it help differentiate the various CA sectors from one another. The subiculum follows CA1 and is not clearly laminated. The zone of transition between CA1 and subiculum is called the prosubiculum (figure 2G).

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2. Cytoarchitecture of the human hippocampus(A-C,G), entorhinal cortex (D-F), and cholinergic neurons of the basal forebrain (H). A-G are photomicrographs of Nissl-stained sections. (A) Low-power photomicrograph of the hippocampus. All sectors of the hippocampus are present in this micrograph. DG = dentate gyrus; CA1-CA4 = the four sectors of Ammon's horn; ProS = prosubiculum; Sub = subiculum. (B) Higher-power photomicrograph showing the dentate gyrus and CA3-CA4 of hippocampus. G1 = granule cell layer of dentate gyrus; ml = molecular layer of dentate gyrus. The polymorphic layer of dentate gyrus is located immediately above the granule cell layer in this micrograph. (C) CA1-CA3 sectors of Ammon's horn. Only the initial portions of CA1 are shown. Pyl = pyramidal cell layer; ml = molecular cell layer of Ammon's horn. (D) Low-power photomicrograph of entorhinal cortex and adjacent structures. Ento= entorhinal cortex; Amy = amygdala; Pri = perirhinal cortex; CS = collateral sulcus. (E) Higher-power micrograph of the section shown in D, allowing the identification of six layers (1-6) in the entorhinal cortex. Arrows point to layer 2 stellate cell islands. (F) High-power micrograph of stellate cell islands of layer 2 in the entorhinal cortex. (G) Section through the hippocampus, depicting the subiculum and adjacent regions. Arrows point to borders of prosubiculum with the subiculum and the CA1. (H) Choline acetyltransferase-immunoreactive cholinergic neurons in the basal forebrain(nucleus basalis of Meynert; Ch4).

The entorhinal cortex is a paralimbic area and is therefore cytoarchitectonically more differentiated than the hippocampus but less so compared with isocortical zones2,30(figures 2D and E). It is situated in the anterior aspects of the parahippocampal gyrus, adjacent to the amygdala and the anterior portions of the hippocampus, and is demarcated inferiorly by the collateral sulcus. The transition between entorhinal cortex and temporal isocortex occurs in the perirhinal cortex, located deep within the banks of the collateral sulcus. The entorhinal cortex contains six identifiable layers(figure 2E), most of which are different from isocortical layers.30 Layer I contains few neurons. Layer II is characterized by islands of large stellate cells (figures 2E and F). Layer III is thick and sparsely populated with pyramidal neurons. Layer IV is cell-free and is therefore termed the lamina dissecans. Layer V is densely populated by polymorphic neurons, and layer VI contains diffusely distributed polymorphic neurons.

Consistent with the pattern of cortical connectivity discussed earlier, virtually all cortical input to the hippocampus originates in the adjacent paralimbic area, the entorhinal cortex (figure 3). Therefore, the hippocampus has no direct access to input from primary sensory areas or to information processed in association cortical areas. The entorhinal cortex is interconnected with other paralimbic cortical zones and, more substantially, with the perirhinal and posterior parahippocampal cortices.3,31,32 The latter two areas, in turn, receive input from paralimbic zones such as the insula, and from unimodal and particularly multimodal association areas such as the posterior parietal cortex, prefrontal cortex, and association cortical areas in the temporal lobe.3,33,34 The integrated information, which is channeled to the entorhinal cortex, is further processed within this structure and is then conveyed to the hippocampus. The input to the hippocampus originates primarily in layers II (stellate cell islands) and III and secondarily in layers V and VI of the entorhinal cortex.3,31,32 This input terminates on the dendrites of granule cells in the outer two-thirds of the molecular layer of the DG and, less prominently, on the dendrites of pyramidal neurons in the molecular layer in CA1-CA3 and the subiculum.6,35 The hippocampus also receives input from the hypothalamus and subcortical components of the limbic system, such as the septum and amygdala.6

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 3. Diagram depicting cortical input to the hippocampus. Input from multimodal (and to a smaller extent unimodal) association areas and many paralimbic regions converge on the entorhinal cortex. The entorhinal cortex, in turn, projects prominently to the hippocampus (via the perforant path). The hippocampus has no access to cortical input except through the entorhinal cortex. Much of the hippocampal output to other cortical areas also travels through the entorhinal cortex.

Information processing in the hippocampus takes place through tightly wired circuits (see Rosene and Van Hoesen6 for details). Axons of the granule cell layer of DG project to the CA4 and polymorphic layer of DG and, more prominently, to CA3. The former two regions, in turn, project back to the inner one-third of the molecular layer of DG. Axon collaterals from CA3 and probably CA2 project prominently to CA1 and, to a lesser extent locally, to CA2-3. Finally, a major pathway carries information from CA1 to the subiculum.

Hippocampal output originates primarily from the CA1, prosubiculum, and subiculum.6 A major extrinsic projection originating in all three areas carries information to the entorhinal, perirhinal, and posterior parahippocampal cortex and to other paralimbic cortical zones such as the orbitofrontal, cingulate, and retrosplenial cortex. A second extrinsic projection originates in the subiculum and terminates in the mammillary bodies in the hypothalamus. Two other substantial outputs of the hippocampus are to the septum via the subiculum and the CA subfields and to the amygdala via the subiculum, CA1, and particularly the prosubiculum.

In summary, cortical input to the hippocampus is channeled through the entorhinal cortex and, after intrinsic processing through tightly wired circuits, hippocampal output is channeled back to the entorhinal cortex and other paralimbic regions. The hippocampus is also reciprocally interconnected with the hypothalamus and with a number of subcortical components of the limbic system.

A large body of evidence indicates that certain classes of neurons in the entorhinal cortex and hippocampus are selectively vulnerable to tangle formation.36,37 In the cerebral cortex, neurofibrillary tangles first appear in the entorhinal cortex.38-40 These early tangles are observed, primarily within the stellate cells of layer II (figures 4A and B). From this restricted locus, tangle formation appears to spread to involve progressively more of the cerebral cortex.39,40 The first stages of this spread are marked by an increase in the number of tangles in the entorhinal cortex, the appearance of tangles in the pyramidal neurons of CA1 and subiculum (figures 4C-F), and increased appearance of tangle-bearing neurons in other limbic and paralimbic regions.39 Later, the number of tangles in the above structures is increased and tangles appear in neocortical regions, particularly in association areas. Still later, the density of tangles shows an increase in all of the above areas to produce widespread tangle distribution in the end stages of AD. Even at the late stages of the disease, however, the entorhinal cortex and hippocampus appear to display among the highest densities of tangles compared to other cortical regions.20,21 (figures 4A-F). In addition to susceptibility to tangle formation, the entorhinal cortex, the CA1, and the subiculum display early and substantial accumulation of neuropil threads, neuronal loss, decrease in dendritic extent, and loss of synapses.41-47 Early AD pathology therefore appears to disrupt the circuitry responsible for both hippocampal input and output.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 4. Cytoskeletal pathology in the entorhinal cortex (A,B), hippocampus (C-F), and cholinergic neurons of the basal forebrain (G) in Alzheimer's disease (AD). These sites are vulnerable to early and severe pathology in AD. (A) Hyperphosphorylated τ(PH-τ)-immunoreactive structures in the entorhinal cortex of a mildly demented AD brain. Many tangles are present, especially in layers 2, 3, and 5. Most of the stellate neurons of layer 2 contain tangles. (B) Higher-power micrograph of the section of entorhinal cortex shown in A. Straight arrows point to tangles in stellate cells of layer 2 islands, many of which are affected. Curved arrows point to tangles in smaller pyramidal neurons in layer 3. This pattern of pathology disrupts cortical input to the hippocampus that is conveyed via the entorhinal cortex. Note that a high density of neuropil threads (small arrows) is also present in this area. (C) PH-τ-positive tangles in the CA1 pyramidal neurons of the hippocampus. Small arrows point to PH-τ positive neurites in plaques. (D) PH-τ-stained section showing relatively heavy concentration of tangles in CA1 of the hippocampus and virtual sparing of the dentate gyrus (DG) and the rest of the CA field. (E) Higher-power photomicrograph of CA1 showing the higher density of PH-τ-positive tangles. Note that a high density of neuropil threads (small arrows) is also present in this area. (F) PH-τ-positive neurofibrillary tangles and neuropil threads (small arrows) in the subiculum (Sub). The severe cytoskeletal pathology in CA1 and Sub disrupts output from the hippocampus to its targets. (G) Thioflavin S-positive tangles within the cholinergic neurons of the basal forebrain (the Ch4 group). Many neuropil threads (small arrows) are intermingled with the tangles.

At present, the reasons for the selective vulnerability of the hippocampus and the entorhinal cortex to AD pathology remain unknown.

Cholinergic system of the basal forebrain. The mammalian cerebral cortex contains a dense plexus of cholinergic axons.7 In the primate brain, the source of this input is extrinsic to the cortex, originating from a large population of neurons in the basal forebrain48,49 (figure 2H). The cholinergic neurons of the basal forebrain can be divided into several groups on the basis of their anatomic location and their preferred cortical targets, as deduced from studies in the monkey. The cholinergic neurons of the medial septum [cholinergic cell group 1 (Ch1)] and the vertical limb of the diagonal band of Broca (Ch2) provide the major cholinergic innervation of the hippocampus, the Ch3 neurons provide the major cholinergic innervation of the olfactory bulb, and the Ch4 neurons provide the major cholinergic innervation of the entire cortical mantle and the amygdala. In the human brain, cortical cholinergic innervation is regionally variable.7,21 The highest density of cholinergic axons is found in core limbic areas such as the amygdala and hippocampus. Paralimbic cortical areas exhibit the next highest density of cholinergic fibers. The unimodal and multimodal association areas contain an intermediate density of cholinergic fibers, and the primary visual cortex (area 17) contains the lowest density. The ACh released from the terminals of cortical cholinergic axons produces its effects through interaction with muscarinic or nicotinic receptors at cholinergic synapses or via passive diffusion.7

One of the major and most consistent neurotransmitter abnormalities in AD is a loss of cortical cholinergic markers.7,50-52 The AD cortex displays a major depletion of its cholinergic axons. The loss of these axons is not uniform but exhibits regional variations.53 The areas with the greatest loss of cholinergic innervation are all in the temporal lobe and include the entorhinal cortex and the hippocampus. The frontal and parietal association areas, as well as the insula and temporal pole, show an intermediate magnitude of loss. The anterior cingulate gyrus, primary motor, primary somatosensory, and primary visual cortex display a minor loss of cholinergic fibers. Consistent with the loss of cortical cholinergic axons, the cholinergic neurons of the basal forebrain from which these axons emanate also display a major loss in AD.7,54,55 In virtually all AD brains, a large population of tangles is observed in the Ch1-Ch4 cell groups27,56,57(figure 4G).

Like the entorhinal cortex, the basal forebrain cholinergic system appears to be selectively vulnerable to the cytoskeletal pathology of AD. A substantial body of evidence indicates that the loss of cortical cholinergic innervation in AD is larger, appears more widespread, and occurs earlier than the loss of other cortically projecting neuronal systems.7,29,58,59 Furthermore, the Ch1-Ch4 cell group is one of the first subcortical areas to display neurofibrillary tangles. Therefore, in mildly demented cases, or in normal cases that show some tangles within the entorhinal cortex, the cholinergic neurons of the basal forebrain almost always contain a variable number of tangles.60-62

Recent evidence provides a possible reason for the selective vulnerability of the basal forebrain cholinergic system in AD. In the primate, but not in the rodent, the overwhelming majority of the Ch1-Ch4 neurons contain the calcium binding protein calbindin-D28k (CalB).63 In the human brain these neurons display a selective loss of CalB in the course of normal aging.64,65 The age-related loss of CalB is selective, in that other neurochemicals in the Ch1-Ch4 neurons are preserved and CalB is not lost from other neurons in the aged brain. CalB binds calcium with high affinity and is therefore able to regulate intracellular calcium levels. The loss of CalB would deprive the aging cholinergic neurons of one mechanism for balancing intracellular calcium and may result in high intracellular calcium concentrations that are lethal to neurons. In this manner, the age-related loss of CalB would leave the basal forebrain cholinergic neurons vulnerable to any pathologic insults with the potential to increase intracellular calcium levels, including the pathology of AD.

Consequences of selective vulnerability. The early and severe pathology in the entorhinal cortex, CA1, and subiculum discussed above leads to a virtual isolation of the hippocampus.36,37 Tangle formation and neuronal loss in the entorhinal cortex, combined with pathology in other paralimbic areas, deprive the hippocampus of much of its cortical input and access to information concerning the external world. Damage to the CA1 and subiculum prevents outflow of information from the hippocampus. Therefore, the neuronal circuitry that enables the hippocampus to execute its normal functions is severely disrupted in AD.

It is now well established that the hippocampus is intimately involved in the neural processing of memory. Specifically, the hippocampus and structures with which it is reciprocally connected are believed to be essential for establishing long-term memory for facts and events.66,67 In nonhuman primates, lesions of the hippocampus produce severe deficits in learning and memory.66,68-70 In humans, lesions in the hippocampus result in amnesia.66,67 Destruction of structures with hippocampal interconnections, such as the entorhinal, perirhinal, and posterior parahippocampal cortices, amygdala, and the mammillary bodies in the hypothalamus, have also been shown to interfere with memory processing in primates.34,66,71-73 Some of these structures, such as the entorhinal cortex and amygdala, are vulnerable to severe pathology in AD. On the basis of the above evidence, it has been suggested that the relatively early isolation of the hippocampus and the pathology of structures that are related to it comprise one of the main substrates for the severe memory deficit observed in AD patients.36,37

The basal forebrain cholinergic system also appears to be involved in the neural processing of learning and memory as well as attention. With few exceptions,74,75 interference with the basal forebrain cholinergic system interferes with learning and memory. Lesions of the cholinergic cells of the basal forebrain deplete the cortex of its cholinergic innervation and impair learning and memory in a number of animal species, including primates.76-79 The cholinergic basis of this deficit was demonstrated through the reversibility of memory loss by cholinergic agonists.80-82 In humans, cholinergic antagonists such as scopolamine have been shown to interfere with learning in young volunteers and to cause memory deficits.83 Recent evidence indicates that the basal forebrain cholinergic system may contribute to learning and memory by influencing the ability of the organism to pay attention to relevant stimuli in its environment.74,75,84 On the basis of the evidence presented here, it is reasonable to assume that the early loss of the basal forebrain cholinergic projection to cortex provides a second substrate for the memory deficit in AD.

In summary, the neural circuits that are selectively vulnerable to AD pathology are those involved in learning and memory. This vulnerability is a probable reason for the clinical memory loss that constitutes the most salient and early symptom in this disorder. The high correlation observed between pathology in these circuits and memory loss, as well as other cognitive symptoms in AD, lends further support to this contention.18,39,40,51,52,85

Therapeutic implications. At present there are no therapeutic strategies that address the selective vulnerability of the hippocampus and related structures to AD pathology. Similar to the rest of the cerebral cortex, the major transmitter used in the hippocampal pathways is glutamate.18,39,40 Many of the input, output, and intrinsic neurons of the hippocampus are rich in glutamate.68,86,87 Furthermore, the hippocampus and the entorhinal cortex contain a high density of several types of glutamate receptors.88-90 In AD, alterations in glutamate and its receptors have been described in the above structures and pathways.91-96 A major problem with application of free glutamate or glutamate receptor agonists is that these agents can be extremely toxic to neurons. For this reason, glutamatergic transmitter replacement therapy in AD would be difficult at best. It therefore, appears that the major therapeutic approach in relation to hippocampal vulnerability would be one that attempts to arrest the formation of pathologic lesions and neuronal loss. At present, no such therapeutic approaches exist.

In contrast to the hippocampus, the basal forebrain cholinergic system has been a target of intense therapeutic attention in AD. Most efforts in this area have concentrated on the development and application of acetylcholinesterase (AChE) inhibitors. The rationale for this approach is to inhibit ACh degradation by AChE and thus increase the available pool of this transmitter. Many trials of AChE inhibitors have been undertaken. A major problem has been the side effects, including toxicity, of some AChE inhibitors.97,98 Despite this problem, most trials have demonstrated improvements in cognitive performance in AD patients after application of AChE inhibitors.99-102 The magnitude of this improvement, however, has been small, and major changes in cognitive abilities have been reported in relatively few patients. In AD brains, AChE is also found in the overwhelming majority of plaques and tangles and may participate in the genesis or deleterious effects of these lesions.103,104 Therefore, a secondary benefit of AChE inhibitors in AD may be inhibition of this enzyme in plaques and tangles. A second approach in cholinergic therapy in AD is concentrated on the application of selective agonists of muscarinic and nicotinic cholinergic receptors.105-108 This effort, however, is relatively new and will need to be proved effective for future use.

A major problem in relation to any therapeutic approach directed toward the hippocampus or the basal forebrain cholinergic system is the early vulnerability of these areas to AD pathology. By the time the clinical symptoms appear, both of these structures show major and severe pathology. For therapies to be effective, early diagnosis of AD is necessary. Therefore, future efforts at therapy must be combined with an equally intense effort at developing tools capable of early diagnosis of AD, preferably at a preclinical stage before the onset of cognitive symptoms.

Acknowledgments

The preparation of this review was made possible in part by grants from the National Institute of Aging (AG10282) and the Bayer Corporation. We thank Daniel Kuznetsov for expert technical assistance.

Footnotes

  • Series editor: Jeffrey L. Cummings MD

References

  1. 1.↵
    Sanides F. Functional architecture of motor and sensory cortices in primates in light of a new concept of neocortex evolution. In: Noback CR, Montagna W, eds. The primate brain. New York: Appleton-Century-Crofts, 1970:137-208.
  2. 2.↵
    Mesulam MM. Patterns of behavioral neuroanatomy: association areas, the limbic system and hemispheric specialization. In: Mesulam MM, ed. Principles of behavioral neurology. Philadelphia: FA Davis, 1985:1-70.
  3. 3.↵
    Van Hoesen GW, Pandya DN. Some connections of the entorhinal (area 28) and perirhinal (area 35) cortices of the rhesus monkey. I. Temporal lobe afferents. Brain Res 1975;95:1-24.
    OpenUrlCrossRefPubMed
  4. 4.
    Pandya DN, Van Hoesen GW, Mesulam MM. Efferent connections of the cingulate gyrus in the rhesus monkey. Exp Brain Res 1981;42:319-330.
    OpenUrl
  5. 5.
    Mesulam MM, Mufson EJ. Insula of the old world monkey. Part III. Efferent cortical output and comments on function. J Comp Neurol 1982;212:38-52.
    OpenUrl
  6. 6.↵
    Rosene DL, Van Hoesen W. The hippocampal formation for the primate brain. A review of some comparative aspects of cytoarchitecture and connections. In: Jones EG, Peters A, eds. Cerebral cortex. 6th ed. New York: Plenum Publishing, 1987:345-456.
  7. 7.↵
    Geula C, Mesulam MM. Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. In: Terry RD, Katzman R, Bick KL, eds. Alzheimer disease. New York: Raven Press, 1994:263-291.
  8. 8.↵
    Alzheimer A. A unique illness involving the cerebral cortex. In: Rothenberg DA, Hochberg FH, eds. Neurological classics in modern translation. London: Hafner Press, 1977:41-43.
  9. 9.↵
    Terry RD, Wisniewski HM. Ultrastructure of senile dementia and of experimental analogues. In: Gaitz CM, ed. Aging and the brain. New York: Plenum Press, 1972:89-116.
  10. 10.↵
    Lorenzo A, Yankner BA. β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA 1994;91:12243-12247.
    OpenUrlFREE Full Text
  11. 11.↵
    Mena R, Wischik CM, Novak M, Milstein C, Cuello C. A progressive deposition of paired helical filaments (PHF) in the brain characterizes the evolution of dementia in Alzheimer's disease. J Neuropathol Exp Neurol 1991;50:474-490.
    OpenUrl
  12. 12.↵
    Trojanowski JQ, Shin RW, Schmidt ML, Lee VM. Relationship between plaques, tangles and dystrophic processes in Alzheimer's disease. Neurobiol Aging 1995;16:335-345.
    OpenUrl
  13. 13.↵
    Selkoe DJ. Normal and abnormal biology of theβ-amyloid precursor protein. Annu Rev Neurosci 1994;17:489-517.
    OpenUrl
  14. 14.
    Yankner BA. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 1996;16:921-932.
    OpenUrlCrossRefPubMed
  15. 15.↵
    Rafalowski J, Barcikowska M, Wen GY, Wisniewski HM. Laminar distribution of neuritic plaques in normal aging, Alzheimer's disease and Down's syndrome. Acta Neuropathol (Berl) 1988;77:21-25.
    OpenUrl
  16. 16.
    Sparks DL, Hunsaker JC III, Scheff SW, Krysco RJ, Henson JL, Markesbery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging 1990;11:601-607.
    OpenUrl
  17. 17.
    Giannakopoulos P, Hof PR, Mottier S, Michel JP, Bouras C. Neuropathological changes in the cerebral cortex of 1258 cases from a geriatric hospital: retrospective clinicopathological evaluation of a 10-year autopsy population. Acta Neuropathol (Berl) 1994;87:456-468.
    OpenUrl
  18. 18.↵
    Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42:631-639.
    OpenUrlPubMed
  19. 19.↵
    Berg L, McCall DW, Miller JP, Morris JC. Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. Arch Neurol 1993;50:349-358.
    OpenUrl
  20. 20.↵
    Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cerebr Cortex 1991;1:103-116.
    OpenUrlPubMed
  21. 21.
    Geula C, Mesulam MM, Saroff DM, Wu CK. Relationship between plaques, tangles and loss of cortical cholinergic fibers in Alzheimer's disease. J Neuropathol Exp Neurol 1998;57:63-75.
    OpenUrl
  22. 22.↵
    Coleman PD, Flood DG. Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol Aging 1987;8:521-545.
    OpenUrl
  23. 23.
    Gomez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997;41:17-24.
    OpenUrl
  24. 24.↵
    Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572-580.
    OpenUrl
  25. 25.
    Scheff SW, DeKosky ST, Price DA. Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol Aging 1990;11:29-37.
    OpenUrlPubMed
  26. 26.
    Catala I, Ferrer I, Galofre E, Fabregues I. Decreased numbers of dendritic spines on cortical pyramidal neurons in dementia. A quantitative Golgi study on biopsy samples. Hum Neurobiol 1988;6:255-259.
    OpenUrl
  27. 27.↵
    German DC, White CL III, Sparkman DR. Alzheimer's disease: neurofibrillary tangles in nuclei that project to the cerebral cortex. Neuroscience 1987;21:305-312.
    OpenUrl
  28. 28.
    Mann DMA, Yates PO, Marcyniuk B. Correlation between senile plaque and neurofibrillary tangle counts in cerebral cortex and neuronal counts in cortex and subcortical structures in Alzheimer's disease. Neurosci Lett 1985;56:51-55.
    OpenUrl
  29. 29.
    D'Amato RJ, Zweig RM, Whitehouse PJ, et al. Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol 1987;22:229-236.
    OpenUrlCrossRefPubMed
  30. 30.↵
    Insausti R, Tunon T, Sobreviela T, Insausti AM, Gonzalo LM. The human entorhinal cortex: a cytoarchitectonic analysis. J Comp Neurol 1995;355:171-198.
    OpenUrlCrossRefPubMed
  31. 31.
    Insausti R, Amaral DG, Cowan WM. The entorhinal cortex of the monkey: II. Cortical afferents. J Comp Neurol 1987;264:356-395.
    OpenUrl
  32. 32.
    Suzuki WA. Neuroanatomy of the monkey entorhinal, perirhinal and parahippocampal cortices: Organization of cortical inputs and interconnections with amygdala and striatum. Semin Neurosci 1996;8:3-12.
    OpenUrlCrossRef
  33. 33.
    Stefanacci L, Suzuki WA, Amaral DG. Organization of connections between the amygdaloid complex and the perirhinal and parahippocampal cortices in macaque monkeys. J Comp Neurol 1996;375:552-582.
    OpenUrl
  34. 34.↵
    Suzuki WA, Amaral DG. Perirhinal and parahippocampal cortices of the macaque monkey: cortical afferents. J Comp Neurol 1994;350:497-533.
    OpenUrl
  35. 35.
    Witter MP, Amaral DG. Entorhinal cortex of the monkey: V. Projections to the dentate gyrus, hippocampus, and subicular complex. J Comp Neurol 1991;307:437-459.
    OpenUrl
  36. 36.↵
    Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 1984;225:1168-1170.
    OpenUrl
  37. 37.
    Van Hoesen GW, Hyman BT, Damasio AR. Cell-specific pathology in neural systems of the temporal lobe in Alzheimer's disease. Prog Brain Res 1986;70:321-335.
    OpenUrlCrossRefPubMed
  38. 38.↵
    Braak H, Braak E. On areas of transition between entorhinal allocortex and temporal isocortex in the human brain. Normal morphology and lamina specific pathology in Alzheimer's disease. Acta Pathol 1985;68:325-332.
    OpenUrl
  39. 39.↵
    Braak H, Braak E. Neuropathological staging of Alzheimer's disease. Acta Neuropathol (Berl) 1991;82:239-259.
    OpenUrl
  40. 40.
    Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging 1991;12:295-312.
    OpenUrl
  41. 41.↵
    Lippa CF, Hamos JE, Pulaski-Salo D, DeGennaro LJ, Drachman DA. Alzheimer's disease and aging: effects on perforant pathways perikarya and synapses. Neurobiol Aging 1992;13:405-411.
    OpenUrl
  42. 42.
    Davies DC, Horwood N, Isaacs SL, Mann DM. The effect of age and Alzheimer's disease on pyramidal neuron density in the individual fields of the hippocampal formation. Acta Neuropathol (Berl) 1992;83:510-517.
    OpenUrl
  43. 43.
    Flood DG. Region-specific stability of dendritic extent in normal human aging and regression in Alzheimer's disease. II. Subiculum. Brain Res 1991;540:83-95.
    OpenUrl
  44. 44.
    Hanks SD, Flood DG. Region-specific stability of dendritic extent in normal human aging and regression in Alzheimer's disease. I. CA1 of hippocampus. Brain Res 1991;540:63-82.
    OpenUrl
  45. 45.
    Terry RD, Peck A, DeTeresa R, Schechter R, Horoupian DS. Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol 1981;10:184-192.
    OpenUrlPubMed
  46. 46.
    Gomez-Isla T, Price JL, McKeel DWJ, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 1996;16:4491-4500.
    OpenUrl
  47. 47.
    Wakabayashi K, Honer WG, Masliah E. Synapse alterations in the hippocampal-entorhinal formation in Alzheimer's disease with and without Lewy body disease. Brain Res 1994;667:24-32.
    OpenUrl
  48. 48.↵
    Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis(substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 1983;214:170-197.
    OpenUrlPubMed
  49. 49.
    Mesulam MM, Geula C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J Comp Neurol 1988;275:216-240.
    OpenUrl
  50. 50.
    Perry EK. The cholinergic system in old age and Alzheimer's disease. Age Aging 1980;9:1-8.
    OpenUrlPubMed
  51. 51.
    DeKosky ST, Harbaugh RE, Schmitt FA, et al. Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlates. Ann Neurol 1992;32:625-632.
    OpenUrl
  52. 52.
    Bierer LM, Haroutunian V, Gabriel S, et al. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem 1995;64:749-750.
    OpenUrl
  53. 53.↵
    Geula C, Mesulam MM. Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease. Cerebr Cortex 1996;6:165-177.
    OpenUrlPubMed
  54. 54.
    Lehericy S, Hirsch EC, Cervera-Pierot P, et al. Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease. J Comp Neurol 1993;330:15-31.
    OpenUrlCrossRefPubMed
  55. 55.
    Whitehouse PJ, Hedreen JC, White CL, Price DL. Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 1983;13:243-348.
    OpenUrlCrossRefPubMed
  56. 56.
    Saper CB, German DC, White CL III. Neuronal pathology in the nucleus basalis and associated cell groups in senile dementia of the Alzheimer's type: possible role in cell loss. Neurology 1985;35:1089-1095.
    OpenUrlAbstract/FREE Full Text
  57. 57.
    Mann DMA, Yates PO, Marcyniuk B. Changes in nerve cells of the nucleus basalis of Meynert in Alzheimer's disease and their relationship to aging and to accumulation of lipofuscin pigment. Mech Aging Dev 1984;25:189-204.
    OpenUrlPubMed
  58. 58.
    Perry EK, Blessed G, Tomlinson BE, et al. Neurochemical activities in human temporal lobe related to aging and Alzheimer-type changes. Neurobiol Aging 1981;2:251-256.
    OpenUrl
  59. 59.
    Bowen DM, Benton JS, Spillane JA, Smith CCT, Allen SJ. Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients. J Neurol Sci 1982;57:191-202.
    OpenUrlCrossRefPubMed
  60. 60.↵
    Mann DMA, Tucker CM, Yates PO. The topographic distribution of senile plaques and neurofibrillary tangles in the brains of non-demented persons of different ages. Neuropathol Appl Neurobiol 1987;13:123-139.
    OpenUrlCrossRefPubMed
  61. 61.
    Mizutani T, Shimada H. Neuropathological background of twenty-seven centenarian brains. J Neurol Sci 1992;108:168-177.
    OpenUrlCrossRefPubMed
  62. 62.
    Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992;42:1681-1688.
    OpenUrlPubMed
  63. 63.↵
    Geula C, Schatz CR, Mesulam MM. Differential localization of NADPH-diaphorase and calbindin-D28k within the cholinergic neurons of the basal forebrain, striatum and brainstem in the rat, monkey, baboon and human. Neuroscience 1993;54:461-476.
    OpenUrl
  64. 64.↵
    Wu CK, Mesulam MM, Geula C. Age-related loss of calbindin from human basal forebrain cholinergic neurons. Neuroreport 1997;8:2209-2213.
    OpenUrl
  65. 65.
    Wu CK, Geula C. Selective loss of calbindin-D28k from cholinergic neurons of human basal forebrain in aging and Alzheimer's disease. In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM, eds. Alzheimer's disease: biology, diagnosis and therapeutics. New York: John Wiley & Sons, 1997:297-302.
  66. 66.↵
    Squire LR, Zola-Morgan S. The medial temporal lobe memory system. Science 1991;253:1380-1386.
    OpenUrl
  67. 67.
    Squire LR, Zola-Morgan S. Memory: brain systems and behavior. Trends Neurol Sci 1988;11:170-175.
    OpenUrlPubMed
  68. 68.↵
    Grandes P, Streit P. Effect of perforant path lesion on pattern on glutamate-like immunoreactivity in rat dentate gyrus. Neuroscience 1991;41:391-400.
    OpenUrl
  69. 69.
    Baylis GC, Moore BO. Hippocampal lesions impair spatial response selection in the primate. Exp Brain Res 1994;98:110-118.
    OpenUrlPubMed
  70. 70.
    Parkinson JK, Murray EA, Mishkin M. A selective mnemonic role for the hippocampus in monkeys: memory for the location of objects. J Neurosci 1988;8:4159-4167.
    OpenUrl
  71. 71.
    Parker A, Gaffan D. Mammillary body lesions in monkeys impair object-in-place memory: functional unity of the fornix-mammillary system. J Cogn Neurosci 1997;9:512-521.
    OpenUrlPubMed
  72. 72.
    Suzuki WA, Zola-Morgan S, Squire LR, Amaral DG. Lesions of the perirhinal and parahippocampal cortices in the monkey produce long-lasting memory impairment in the visual and tactual modalities. J Neurosci 1993;13:2430-2451.
    OpenUrl
  73. 73.
    Gaffan D. Dissociated effects of perirhinal cortex ablation, fornix transection and amygdalectomy: evidence for multiple memory systems in the primate temporal lobe. Exp Brain Res 1994;99:411-422.
    OpenUrl
  74. 74.↵
    Stoehr JD, Mobley SL, Roice D, et al. The effects of selective cholinergic basal forebrain lesions and aging upon expectancy in the rat. Neurobiol Learn Mem 1997;67:214-227.
    OpenUrl
  75. 75.
    Voytko ML, Olton DS, Richardson RT, Gorman LK, Tobin JR, Price DL. Basal forebrain lesions in monkeys disrupt attention but not learning and memory. J Neurosci 1994;14:167-186.
    OpenUrlAbstract
  76. 76.↵
    Walsh TJ, Herzog CD, Gandhi C, Stackman RW, Wiley RG. Injection of IgG 192-saporin into the medial septum produces cholinergic hypofunction and dose-dependent working memory deficits. Brain Res 1996;726:69-79.
    OpenUrl
  77. 77.
    Leanza G, Muir J, Nilsson OG, Wiley RG, Dunnett SB, Bjorklund A. Selective immunolesioning of the basal forebrain cholinergic system disrupts short-term memory in rats. Eur J Neurosci 1996;8:1535-1544.
    OpenUrlPubMed
  78. 78.
    Berger-Sweeney J, Heckers S, Mesulam MM, Wiley RG, Lappi DA, Sharma M. Differential effects on spatial navigation of immunotoxin-induced cholinergic lesions of the medial septal area and nucleus basalis magnocellularis. J Neurosci 1994;14:4507-4519.
    OpenUrl
  79. 79.
    Irle E, Markowitsch HL. Basal forebrain-lesioned monkeys are severely impaired in tasks of association and recognition memory. Ann Neurol 1987;22:735-743.
    OpenUrl
  80. 80.↵
    Winkler J, Suhr ST, Gage FH, Thal LJ, Fisher LJ. Essential role of neocortical acetylcholine in spatial memory. Nature 1995;375:484-487.
    OpenUrlPubMed
  81. 81.
    Dokla CP, Thal LJ. Effect of cholinesterase inhibitors on Morris water task behavior following lesions of the nucleus basalis magnocellularis. Behav Neurosci 1988;102:861-871.
    OpenUrl
  82. 82.
    Aigner TG, Mitchell SJ, Aggleton JP, et al. Effects of scopolamine and physostigmine on recognition memory in monkeys with ibotenic-acid lesions of the nucleus basalis of Meynert. Psychopharmacology 1987;92:292-300.
    OpenUrl
  83. 83.↵
    Drachman DA, Leavitt J. Human memory and the cholinergic system: a relationship to aging? Arch Neurol 1974;30:113-121.
    OpenUrl
  84. 84.
    Muir JL, Dunnett SB, Robbins TW, Everitt BJ. Attentional functions of the forebrain cholinergic systems: effects of intraventricular hemicholinium, physostigmine, basal forebrain lesions and intracortical grafts on a multiple-choice serial reaction time task. Exp Brain Res 1992;89:611-622.
    OpenUrl
  85. 85.
    Wilcock GK, Esiri MM, Bowen DM, Smith CCT. Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci 1982;57:407-417.
    OpenUrl
  86. 86.
    Sandler R, Smith AD. Coexistence of GABA and glutamate in mossy fiber terminals of the primate hippocampus: an ultrastructural study. J Comp Neurol 1991;303:177-192.
    OpenUrlPubMed
  87. 87.
    Ottersen OP, Storm-Mathisen J. Different neuronal localization of aspartate-like and glutamate-like immunoreactivities in the hippocampus of rat, guinea pig and Senegalese baboon (Papio papio), with a note on the distribution of gamma-aminobutyrate. Neuroscience 1985;16:589-606.
    OpenUrl
  88. 88.↵
    Longson D, Longson CM, Jones EG. Localization of CAM II kinase-alpha, GAD, GluR2 and GABA(A) receptor subunit mRNAs in the human entorhinal cortex. Eur J Neurosci 1997;9:662-675.
    OpenUrlPubMed
  89. 89.
    Jansen KL, Faull RL, Dragunow M. Excitatory amino acid receptors in the human cerebral cortex: a quantitative autoradiographic study comparing the distributions of [3H]TCP, [3H]glycine, L-[3H]glutamate,[3H]AMPA and [3H]kainic acid binding sites. Neuroscience 1989;32:587-607.
    OpenUrl
  90. 90.
    Ikonomovic MD, Sheffield R, Armstrong DM. AMPA-selective glutamate receptor subtype immunoreactivity in the aged human hippocampal formation. J Comp Neurol 1995;359:239-252.
    OpenUrl
  91. 91.↵
    Ikonomovic MD, Sheffield R, Armstrong DM. AMPA-selective glutamate receptor subtype immunoreactivity in the hippocampal formation of patients with Alzheimer's disease. Hippocampus 1995;5:469-486.
    OpenUrlPubMed
  92. 92.
    Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann Neurol 1996;40:759-766.
    OpenUrl
  93. 93.
    Ulas J, Brunner LC, Geddes JW, Choe W, Cotman CW. N-methyl-D-aspartate receptor complex in the hippocampus of elderly, normal individuals and those with Alzheimer's disease. Neuroscience 1992;49:45-61.
    OpenUrl
  94. 94.
    Hyman BT, Van Hoesen GW, Damasio AR. Alzheimer's disease: glutamate depletion in the hippocampal perforant pathway zone. Ann Neurol 1987;22:37-40.
    OpenUrl
  95. 95.
    Sasaki H, Muramoto O, Kanazawa I, Arai H, Kosaka K, Iizuka R. Regional distribution of amino acid transmitters in postmortem brains of presenile and senile dementia of Alzheimer type. Ann Neurol 1986;19:263-269.
    OpenUrl
  96. 96.
    Geddes JW, Monaghan DT, Cotman CW, Lott IT, Kim RC, Chui HC. Plasticity of hippocampal circuitry in Alzheimer's disease. Science 1985;230:1179-1181.
    OpenUrl
  97. 97.↵
    Shaddock JG, Feuers RJ, Chou MW, Swenson DH, Casciano DA. Genotoxicity of tacrine in primary hepatocytes isolated from B6C3F1 mice and aged ad libitum and calorie restricted Fischer 344 rats. Mut Res 1995;344:79-88.
    OpenUrl
  98. 98.
    Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-998.
    OpenUrl
  99. 99.↵
    Amberla K, Nordberg A, Viitanen M, Winblad B. Long-term treatment with tacrine (THA) in Alzheimer's disease-evaluation of neuropsychological data. Acta Neurol Scand 1993;149:(suppl):55-57.
  100. 100.
    Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease. Alz Dis Assoc Disord 1996;10:124-131.
    OpenUrl
  101. 101.
    Thal LJ, Schwartz G, Sano M, et al. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group. Neurology 1996;47:1389-1395.
    OpenUrlAbstract/FREE Full Text
  102. 102.
    Raskind MA, Sadowsky CH, Sigmund WR, Beitler PJ, Auster SB. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease. Arch Neurol 1997;54:836-840.
    OpenUrl
  103. 103.↵
    Geula C, Mesulam MM. Special properties of cholinesterases in the cerebral cortex of Alzheimer's disease. Brain Res 1989;498:185-189.
    OpenUrlCrossRefPubMed
  104. 104.
    Geula C, Mesulam MM. Cholinesterases and the pathology of Alzheimer's disease. Alz Dis Assoc Disord 1995;9:23-28.
    OpenUrl
  105. 105.↵
    Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997;54:465-473.
    OpenUrl
  106. 106.
    Raffaele KC, Asthana S, Berardi A, et al. Differential response to the cholinergic agonist arecoline among different cognitive modalities in Alzheimer's disease. Neuropsychopharmacology 1996;15:163-170.
    OpenUrlPubMed
  107. 107.
    Buccafusco JJ, Jackson WJ. Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol Aging 1991;12:233-238.
    OpenUrl
  108. 108.
    Mouradian MM, Mohr E, Williams JA, Chase TN. No response to high-dose muscarinic agonist therapy in Alzheimer's disease. Neurology 1988;38:606-608.
    OpenUrl

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (5)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise